Skip to main content Accessibility help
  • Print publication year: 2011
  • Online publication date: April 2011

Chapter 59 - Antimicrobial therapy

Related content

Powered by UNSILO


1. MacDougall C, Polk RE. Variability in rates of use of antibacterials among 130 US hospitals and risk-adjustment models for interhospital comparison. Infect Control Hosp Epidemiol 2008; 29: 203–11.
2. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004; 38: 1279–86.
3. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 2007; 20: 391–408.
4. Finberg RW, Moellering RC, Tally FP, et al. The importance of bactericidal drugs: future directions in infectious disease. Clin Infect Dis 2004; 39: 1314–20.
5. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79–86.
6. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 786–95.
7. Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 1999; 43: 309–11.
8. Lorente L, Jimenez A, Palmero S, et al. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther 2007; 29: 2433–9.
9. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398–402.
10. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925–42.
11. Gadde J, Spence M, Wheeler B, Adkinson NF. Clinical experience with penicillin skin testing in a large inner-city STD clinic. JAMA 1993; 270: 2456–63.
12. Kerr JR. Penicillin allergy: a study of incidence as reported by patients. Br J Clin Pract 1994; 48: 5–7.
13. Salkind AR, Cuddy PG, Foxworth JW. The rational clinical examination. Is this patient allergic to penicillin? An evidence-based analysis of the likelihood of penicillin allergy. JAMA 2001; 285: 2498–505.
14. Robinson JL, Hameed T, Carr S. Practical aspects of choosing an antibiotic for patients with a reported allergy to an antibiotic. Clin Infect Dis 2002; 35: 26–31.
15. Apter AJ, Kinman JL, Bilker WB, et al. Is there cross-reactivity between penicillins and cephalosporins? Am J Med 2006; 119: 354, e11–9.
16. Prescott WA, Kusmierski KA. Clinical importance of carbapenem hypersensitivity in patients with self-reported and documented penicillin allergy. Pharmacotherapy 2007; 27: 137–42.
17. DePestel DD, Benninger MS, Danziger L, et al. Cephalosporin use in treatment of patients with penicillin allergies. J Am Pharm Assoc (2003) 2008; 48: 530–40.
18. Perez Pimiento A, Gomez Martinez M, Minguez Mena Aet al. Aztreonam and ceftazidime: evidence of in vivo cross allergenicity. Allergy 1998; 53: 624–5.
19. Patriarca G, Schiavino D, Lombardo C, et al. Tolerability of aztreonam in patients with IgE-mediated hypersensitivity to beta-lactams. Int J Immunopathol Pharmacol 2008; 21: 375–9.
20. Jensen T, Koch C, Pedersen SS, Hoiby N. Aztreonam for cystic fibrosis patients who are hypersensitive to other beta-lactams. Lancet 1987; 1: 1319–20.
21. Moss RB. Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis. J Allergy Clin Immunol 1991; 87: 78–88.
22. Yu VL. Antimicrobial Therapy and Vaccines: Volume 2: Antimicrobial Agents., 2nd edn. Pittsburgh, PA: ESun Technologies, 2004.
23. Kucers A. The Use of Antibiotics: a Clinical Review of Antibacterial, Antifungal, and Antiviral Drugs, 5th edn. Oxford; Boston: Butterworth-Heinemann, 1997.
24. Bryskier A. Antimicrobial Agents: Antibacterials and Antifungals. Washington, DC: ASM Press, 2005.
25. Mandell GL, Douglas RG, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases., 5th edn. Philadelphia, PA: Churchill Livingstone, 2000.
26. Romano A, Quaratino D, Papa G, Di Fonso M, Venuti A. Aminopenicillin allergy. Arch Dis Child 1997; 76: 513–17.
27. Monte SV, Prescott WA, Johnson KK, Kuhman L, Paladino JA. Safety of ceftriaxone sodium at extremes of age. Expert Opin Drug Saf 2008; 7: 515–23.
28. Martin E, Fanconi S, Kalin P, et al. Ceftriaxone – bilirubin-albumin interactions in the neonate: an in vivo study. Eur J Pediatr 1993; 152: 530–4.
29. Norrby SR. Neurotoxicity of carbapenem antibacterials. Drug Saf 1996; 15: 87–90.
30. Calandra G, Lydick E, Carrigan J, Weiss L, Guess H. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988; 84: 911–18.
31. Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Saf 2007; 30: 657–68.
32. Odio CM, Puig JR, Feris JM, et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. Pediatr Infect Dis J 1999; 18: 581–90.
33. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J Antimicrob Chemother 2007; 60: 788–94.
34. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44: 3883–6.
35. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52: 1330–6.
36. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149–52.
37. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10: R27.
38. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des 2007; 13: 119–26.
39. Brogard JM, Conraux C, Collard M, Lavillaureix J. Ototoxicity of tobramycin in humans: influence of renal impairment. Int J Clin Pharmacol Ther Toxicol 1982; 20: 408–16.
40. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007; 27: 1189–97.
41. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006; 42: 1578–83.
42. Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46: S19–S31.
43. Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J 2003; 22: 1128–32.
44. Andreev E, Koopman M, Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med 1999; 246: 247–52.
45. von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006; 6: 6.
46. Alvarez-Lerma F, Allepuz-Palau A, Garcia MP, et al. Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function. J Chemother 2008; 20: 93–100.
47. Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988; 148: 2389–94.
48. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57: 1–60.
49. Jefferson TO, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2006; 3: CD001265.
50. Mauermann WJ, Nemergut EC. The anesthesiologist's role in the prevention of surgical site infections. Anesthesiology 2006; 105: 413–21.
51. Belda FJ, Aguilera L, García de la Asunción J, et al. Supplemental perioperative oxygen and the risk of surgical wound infection: a randomized controlled trial. JAMA 2005; 294: 2035–42.
52. Greif R, Akça O, Horn EP, Kurz A, Sessler DI. Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection. Outcomes Research Group. N Eng J Med 2000; 342: 161–7.
53. Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. N Engl J Med 1996; 334: 1209–15.
54. Leaper D. Effects of local and systemic warming on postoperative infections. Surg Infect (Larchmt) 2006; 7: S101–3.
55. Sessler DI. Complications and treatment of mild hypothermia. Anesthesiology 2001; 95: 531–43.
56. Sessler DI. Non-pharmacologic prevention of surgical wound infection. Anesthesiol Clin 2006; 24: 279–97.
57. Xiao H, Remick DG. Correction of perioperative hypothermia decreases experimental sepsis mortality by modulating the inflammatory response. Crit Care Med 2005; 33: 161–7.
58. Brandstrup B, Tønnesen H, Beier-Holgersen R. Effects of intravenous fluid restriction on postoperative complications:comparison of two perioperative fluid regimens-a randomized assessor-blinded multicenter trial. Ann Surg 2003; 238: 641–8.
59. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67: 352–60.
60. Holte K, Foss NB, Andersen J, et al. Liberal or restrictive fluid administration in fast track colonic surgery: a randomized double-blind study. Brit J Anaesthesia 2007; 99: 500–8.
61. Agarwal N, Murphy JG, Cayten CG, Stahl WM. Blood transfusion increases the risk of infection after trauma. Arch Surg 1993; 128: 171–6.
62. Ali ZA, Lim E, Motalleb-Zadeh Ret al. Allogenic blood transfusion does not predispose to infection after cardiac surgery. Ann Thorac Surg 2004; 78: 1542–6.
63. Fergusson D, Hébert PC, Lee SK, et al. Clinical outcomes following institution of universal leukoreduction of blood transfusions for premature infants. JAMA 2003; 289: 1950–6.
64. Hébert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003; 289: 1941–9.
65. Houbiers JG, van de Velde CJ, van de Watering LM, et al. Transfusion of red cells is associated with increased incidence of bacterial infection after colorectal surgery: a prospective study. Transfusion 1997; 37: 126–34.
66. Ouattara A, Lecomte P, Le Manach Y, et al. Poor intraoperative blood glucose control is associated with a worsened hospital outcome after cardiac surgery in diabetic patients. Anesthesiology 2005; 103: 687–94.
67. Raghavan M, Marik PE. Anemia, allogenic blood transfusion, and immunomodulation in the critically ill. Chest 2005; 127: 295–307.
68. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Eng J Med 2001; 345: 1359–67.
69. Vriesendorp TM, Morélis QJ, Devries JH, Legemate DA, Hoekstra JB. Early post-operative glucose levels are an independent risk factor for infection after peripheral vascular surgery. Eur J Vasc Endovasc Surg 2004; 28: 520–5.
70. Zerr KJ, Furnary AP, Grunkemeier GL, et al. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 1997; 63: 356–61.
71. Lang K, Boldt J, Suttner S, Haisch G. Colloids versus crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery. Anesth Analg 2001; 93: 405–9.
72. Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38: 1706–15.
73. Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg 2005; 189: 395–404.
74. Dellinger EP, Hausmann SM, Bratzler DW, et al. Hospitals collaborate to decrease surgical site infections. Am J Surg 2005; 190: 9–15.
75. Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008; 299: 1149–57.
76. Robicsek A, Beaumont JL, Paule SM, et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 2008; 148: 1–46.
77. Polk HC, Lopez-Mayor JF. Postoperative wound infection: a prospective study of determinant factors and prevention. Surgery 1969; 66: 97–103.
78. Bamgbade OA, Rutter TW, Nafiu OO, Dorje P. Postoperative complications in obese and nonobese patients. World J Surg 2007; 31: 556–60.
79. Edmiston CE, Krepel C, Kelly H, et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? Surgery 2004; 136: 738–47.
80. Szmuk P, Rabb MF, Baumgartner JE, et al. Body morphology and the speed of cutaneous rewarming. Anesthesiology 2001; 95: 18–21.